Rationale-based design of a targeted therapy for cancer
US9782418B2 · kind B2 · utility
4Cited by
0References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 3, 2014 |
| Grant date | Oct 10, 2017 |
| Priority date | — |
| Expiry date | Dec 3, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/5011
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The methods, compositions, and kits of the invention are related to the discovery that lestaurtinib reduces levels and pathway activity of an SPOP substrate. Accordingly, described herein are methods and compositions for the use of lestaurtinib in downregulating one or more SPOP substrates or signaling pathway activities thereof in a subject in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.